A director at Volvo AB maiden bought 15,000 shares at 262.000SEK and the significance rating of the trade was 91/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Both Q1 revenues and PTP were record-high (both up 11% YOY), powered by strong brokerage income and resilient NII despite falling rates. Activity looks elevated going into Q2, and we see upside potential to NII consensus estimates. The total return profile remains attractive on our expectation of c10% long-term EPS growth and a c5% total yield. We reiterate our BUY and have raised our target price to SEK293 (274).
Q1’s punchy order intake was a positive. However, soft US Truck margins, “slightly” negative pricing, mix headwinds for VCE and FX all point to earnings pressure still not being reflected in consensus (we are c15–16% below on 2025–2026e adj. EBIT after lowering our estimates by another c7%). Although the stock is starting to look attractive fundamentally, we expect sentiment to get worse before it gets better, reiterate our SELL and have cut our target price to SEK240 (280).
Three Directors at BioArctic AB bought 3,120 shares at between 163.200SEK and 164.700SEK. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Growth momentum set to continue Q1 profits reached a new quarterly all-time high, supported by surging customer activity and particularly strong brokerage income. We believe trading intensity is set to remain elevated in Q2, and see potential for further positive consensus earnings revisions. At a 2025e P/E of c20x, the valuation remains undemanding, in our view. We have raised 2025–2026e EPS by 3–6%, our target price to SEK370 (347), and reiterate our BUY.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.